Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Key Points GAAP revenue surged to $4.0 million in Q2 2025, beating analyst expectations by 381.9%. GAAP net loss per share improved to $(0.50) in Q2 2025, slightly better than the estimated $(0.52).

Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial; ...

CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoingCash and cash equivalents of $83.5 million as of June 30, ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI-designed therapies and digital twin technology are ...

HHS says the elimination of 22 mRNA vaccine development projects for COVID-19 and bird flu signals a shift in vaccine ...

Q2 2025 Management View CEO Michael S. Exton stated, "When we entered 2025, if you recall, we're still in the early days of ...

Y-mAbs Therapeutics announced that it would be acquired at a >100% premium relative to recent trading. Click here to read an ...

Ethris begins patient dosing in phase 2a trial of lead mRNA candidate ETH47 for asthma: Munich, Germany Wednesday, August 6, 2025, 18:00 Hrs [IST] Ethris GmbH, a clinical-stage bi ...

Conference call today at 9:00 am ET2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD ...

Purespring Therapeutics has secured approval for its UK clinical trial application (CTA) for a Phase I/II trial of its lead programme, PS-002.